TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms.

MLA

Shah, Mithun Vinod, et al. “TP53 Mutation Variant Allele Frequency of ≥10% Is Associated with Poor Prognosis in Therapy-Related Myeloid Neoplasms.” Blood Cancer Journal, vol. 13, no. 1, Apr. 2023, p. 51. EBSCOhost, https://doi.org/10.1038/s41408-023-00821-x.

APA

Shah, M. V., Tran, E. N. H., Shah, S., Chhetri, R., Baranwal, A., Ladon, D., Shultz, C., Al-Kali, A., Brown, A. L., Chen, D., Scott, H. S., Greipp, P., Thomas, D., Alkhateeb, H. B., Singhal, D., Gangat, N., Kumar, S., Patnaik, M. M., Hahn, C. N., … Hiwase, D. K. (2023). TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer Journal, 13(1), 51. https://doi.org/10.1038/s41408-023-00821-x

Chicago

Shah, Mithun Vinod, Elizabeth Ngoc Hoa Tran, Syed Shah, Rakchha Chhetri, Anmol Baranwal, Dariusz Ladon, Carl Shultz, et al. 2023. “TP53 Mutation Variant Allele Frequency of ≥10% Is Associated with Poor Prognosis in Therapy-Related Myeloid Neoplasms.” Blood Cancer Journal 13 (1): 51. doi:10.1038/s41408-023-00821-x.